Immunome CEO Buys Over $500K in Open Market Shares

summarizeSummary

Immunome Inc.'s CEO, Clay B. Siegall, purchased over $500,000 of company stock in an open market transaction, signaling strong executive confidence.

check_boxKey Events

• CEO Open Market Purchase

  Clay B. Siegall, President and CEO, acquired 25,450 shares of Immunome Inc. common stock for a total value of $500,601.50 on March 27, 2026.

• Executive Confidence Signal

  This substantial direct investment by the company's top executive, made at an average price of $19.67 per share (above the current stock price of $19.096), signals strong belief in the company's valuation and future outlook.

• Increased Direct Holdings

  Following this transaction, the CEO's direct holdings increased to 690,704 shares.

auto_awesomeAnalysis

Immunome Inc.'s President and CEO, Clay B. Siegall, demonstrated strong conviction by acquiring 25,450 shares of company stock in an open market purchase totaling over $500,000. This significant investment, made at an average price of $19.67 per share (slightly above the current stock price of $19.096), signals the top executive's belief in the company's future prospects and potential undervaluation. Such direct insider buying often aligns management's interests with shareholders and can be interpreted as a positive indicator for investors.